Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001

CEC, 1998a. Environmental risk assessment of human medicinal products containing or consisting of GMOs. In: CEC, 1998, Guidelines, Medicinal products for human use: Safety, environment and information. Office for Official Publication of the European Communities, Luxembourg, pp. 135–146. CEC, 1998b. Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market. Off. J. L123 (24/04/1998), pp. 1–63. CEC, 2001. Notice to Applicants. Medicinal Products for Human Use. Presentation and contents of the Dossier Common Technical Document (CTD). The Rules Governing Medicinal Products in the European Union, vol. 2B. European Commission, Brussels. Available from http://dg3.eudra.org/F2/eudralex/vol-2/B/etdoct01.pdf. CEEC, 1965. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. Off. J. 22 (09/02/1965), pp. 369–373. CEEC, 1991. Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market. Off. J. L230 (19/08/1991), pp. l–32. CEEC, 1992. Council Directive 92/32/EEC of 30 April 1992 amending for the seventh time Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Off. J. L154 (05/06/1992), pp. 1–29. CEEC, 1993a. Council Directive 93/39/EEC of 14 June 1993 amending Directives 65/65/EEC, 75/318/EEC and 75/319/EPIC in respect of medicinal products. Off. J. L214 (24/08/1993), pp. 22–30. CEEC, 1993b. Council Regulation (EEC) No 2309/93 of 22 July 1993 laying dawn Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. Off. J. L214 (24/08/1993), pp. 1–21. CPMP. Assessment of potential risks for the environment posed by medicinal products for human use (excluding products containing live genetically modified organisms): Phase I Environmental Risk Assessment III 5504/94 Draft 7. (10/01/95). CSTEE, 2001. Opinion on: Draft CPMP discussion paper on environmental risk assessment of medicinal products for human use (non-GMO containing). C2/JCD/esteeop/CPMP Plenary Meeting, Brussels, 12 June 2001. Available from http://europa.eu.int/comm/food/fs/se/set/out111_en.pdf. ECB, 1999. Technical Guidance Document in Support of Commission Directive 93/67/EEC on Risk Assessment for New Notified Substances and Commission Regulation (EC) No. 1488/94 on Risk Assessment for Existing Substances Office for Official publications of the European Communities, Luxemburg. EMEA, 1997. Environmental risk assessment for veterinary medicinal products other than GMO-containing and immunological products. EMEA/CVMP/055/96. EMEA, London. Available from http://www.emea.eu.int/pdfs/vet/regaffair/005596en.pdf. EMEA, 2000. Guideline on environmental impact assessment (EIAS) for veterinary medicinal products phase 1. VICH Topic GL6 (Ecotoxicity Phase I), Step 7. EMEA/CVMP/VICH/592/98 final. Available from http://www.emea.eu.int/pdfs/vet/vich/059298en.pdf. EMEA, 2001. Draft CPMP discussion paper on environmental risk assessment of non-genetically modified organism (non-GMO) containing medicinal products for human use. CPMP/SWP/4447/00 draft. corr. Available from http://www.emea.eu.int/pdfs/human/swp/444700en.pdf. EDA, 1998. Guidance for Industry. Environmental Assessment of Human Drugs and Biologics Applications. FDA, CDER/CBER, CMC 6, rev. 1. Available from http://www.fda.gov/cber/gdlns/environ.pdf.